Clinical, experimental, and genetic studies on the etiology of central serous chorioretinopathy

Clinical, experimental, and genetic studies on the etiology of central serous chorioretinopathy - Studies on the etiology of central serous chorioretinopathy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42212

Enrollment

825

Registered

2015-04-10

Start date

2015-05-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central serous chorioretinopathy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All participants will be aged above 18 years.;1) Genetic analysis and ophthalmological examination in a CSC patient cohort, and in known families with CSC. * Sporadic CSC: CSC patients who visit or visited the outpatient clinic of the Department of Ophthalmology in either the Leiden University Medical Center or the Rotterdam Eye Hospital. * Familial CSC: CSC patients, who have at least one family member in whom CSC has been detected. ;2) Analysis of serum complement activity in CSC patients and in a healthy control group. * CSC patients who visit the outpatient clinic of the Department of Ophthalmology in the Leiden University Medical Center. Per patient a control will be recruited. For example, the husband or wife of each CSC patient who visits the outpatient clinic of the department of Ophthalmology.;3) Endocrinological analysis of cortisol and testosterone exposure and sensitivity in CSC patients and in controls. * CSC patients who visit the outpatient clinic of the Department of Ophthalmology in the Leiden University Medical Center will be referred to the outpatient clinic of the Department of Endocrinology. ;4) Analysis of the retinal phenotype and choroidal thickness in patients with Cushing*s syndrome, Conn*s syndrome, patients who receive solumedrol (a corticosteroid) during acute rejection of a renal transplant, or post renal transplantation patients who receive corticosteroids. * Patients with Cushing*s syndrome or Conn*s syndrome who visit or visited the outpatient clinic of the Department of Endocrinology and are willing to take part in this study. * Patients receiving solumedrol during acute rejection of a renal transplant, or post renal transplantation patients who receive corticosteroids, who visit or visited the outpatient clinic of the Department of Nephrology and are willing to take part in this study.

Exclusion criteria

Exclusion criteria: For our study no exclusion criteria are applicable.

Design outcomes

Primary

Measure	Time frame
1) Genetic analysis and ophthalmological examination in a CSC patient cohort, and in known families with CSC. * Exome sequencing in patients with familial CSC could reveal genes with a different expression, as compared to healthy controls. These genes could give a clue in studying the aberrant gene expression levels in patients with sporadic CSC. Purpose of study is elucidate the etiology of CSC. 2) Analysis of serum complement activity in CSC patients and in a healthy control group. * Complement activity in patients and in controls will be compared. 3) Endocrinological analysis of cortisol and testosterone exposure and sensitivity in CSC patients and in controls. * Purpose of study is to find possible endocrinological abnormalities in CSC patients. 4) Analysis of the retinal phenotype and choroidal thickness in patients with Cushings syndrome, Conns syndrome, patients who receive solumedrol (a corticosteroid) during acute rejection of a renal transplant, or post renal transplantation patients who receive corticosteroids. Comparison of these results to a control group of patients which do not show hypercortisolism will be done. * Purpose of study is to find abnormalities in retinal phenotype and choroidal thickness in the several patient groups.	—

Measure

Time frame

1) Genetic analysis and ophthalmological examination in a CSC patient cohort, and in known families with CSC. * Exome sequencing in patients with familial CSC could reveal genes with a different expression, as compared to healthy controls. These genes could give a clue in studying the aberrant gene expression levels in patients with sporadic CSC. Purpose of study is elucidate the etiology of CSC. 2) Analysis of serum complement activity in CSC patients and in a healthy control group. * Complement activity in patients and in controls will be compared. 3) Endocrinological analysis of cortisol and testosterone exposure and sensitivity in CSC patients and in controls. * Purpose of study is to find possible endocrinological abnormalities in CSC patients. 4) Analysis of the retinal phenotype and choroidal thickness in patients with Cushing*s syndrome, Conn*s syndrome, patients who receive solumedrol (a corticosteroid) during acute rejection of a renal transplant, or post renal transplantation patients who receive corticosteroids. Comparison of these results to a control group of patients which do not show hypercortisolism will be done. * Purpose of study is to find abnormalities in retinal phenotype and choroidal thickness in the several patient groups.

—

Secondary

Measure	Time frame
Secondary study parameters are non-applicable.	—

Countries

Netherlands

Outcome results